Matthew Fury MD

Oncology•Thornwood, NY

Head & Neck Cancer

Senior Director, Oncology Clinical Sciences, Regeneron Pharmaceuticals

Join to View Full Profile

777 Old Saw Mill River Road, Tarrytown, NYThornwood, NY 10594

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2000 - 2003
State University of New York Downstate Medical Center College of MedicineClass of 2000

Certifications & Licensure

NY State Medical License 2002 - 2025

Clinical Trials

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors Start of enrollment: 2006 Nov 01
Completed
Phase 1
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer Start of enrollment: 2006 Oct 01
Completed
Phase 2
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2007 Jul 01
Completed
Phase 2
Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer Start of enrollment: 2007 Nov 01
Completed
Phase 2
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer Start of enrollment: 2008 Jul 01
Completed
Phase 2
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) Start of enrollment: 2008 Aug 01
Completed
Phase 1
Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer Start of enrollment: 2009 Mar 01
Completed
Phase 1
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer Start of enrollment: 2009 Jul 01
Completed
Phase 1
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma Start of enrollment: 2009 Aug 01
Completed
Phase 2
Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Start of enrollment: 2009 Nov 01
Completed
Phase 1, Phase 2
Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma Start of enrollment: 2010 Dec 28
Completed
Not Applicable
BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors Start of enrollment: 2011 Feb 15
Completed
Phase 1
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2012 Nov 12
Terminated
Phase 1, Phase 2
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) Start of enrollment: 2012 Nov 01
Completed
Phase 1
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors Start of enrollment: 2014 May 14
Completed
Phase 1
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2014 Aug 07
Terminated
Phase 1
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy Start of enrollment: 2014 Jul 28
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, Hee Seung Kim, Yong Man Kim
European Journal of Cancer. 2025-02-05
4 citations
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.
Diwakar Davar, Robert M Morrison, Amiran K Dzutsev, Arivarasan Karunamurthy, Joe-Marc Chauvin
Cancer Cell. 2024-11-11
1 citations
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, Masao Okadome, Kan Yonemori
Cancer Medicine. 2024-09-01